NeuExcell Therapeutics and Spark Therapeutics Collaboration

 

Theobald Associates is pleased to announce the successful completion of a research collaboration agreement between its client NeuExcell Therapeutics and Spark Therapeutics. The research collaboration is in the gene therapy field aimed at developing a safe and effective treatment for patients suffering from Huntington’s Disease. Under the Option License NeuExcell is eligible to receive upfront, R&D and sales milestone payments up to approximately USD 190 million plus product royalties. Further details can be found at: https://www.prnewswire.com/news-releases/neuexcell-therapeutics-and-spark-therapeutics-announce-research-collaboration-agreement-to-develop-a-novel-gene-therapy-for-huntingtons-disease-301369445.html